CTTI

Clinical Trials Transformation Initiative

Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials

Posted on March 7, 2020February 6, 2025 by Hannah Faulkner

Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials

This entry was posted in Investigator Community, Investigator Community, Publications, Related: Investigator Community, Site Planning, Study Operations. Bookmark the permalink.

← Webinar to Provide Findings & Reflections from CTTI’s ICH E6 Renovation Work

Interview Findings: Informing the Renovations to the ICH E6 GCP Guideline →

DISCLAIMER: CTTI encourages the use of all materials listed on this site in the pursuit of improving the clinical trials enterprise. Our recommendations, tools, meeting summaries, and more are available to the public for free. We do ask that you acknowledge the source whenever using or referencing CTTI materials. Read our Citation Policy.

About
Newsroom
Membership
Case Studies
Contact Us

Access to Clinical Trials
Artificial Intelligence
Clinical Trials Landscape
Data Collecting + Reporting
Ensuring Quality
Innovative Trials

Informed Consent
Patient Group Engagement
Real-World Data
Recruitment
Regulatory Submissions + Approvals
Safety + Protection
Site Planning

privacy statement

WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly.